TapewireFind a company

person · Reporting owner

Bigora Sian

Disclosed activity across 1 company

Tapewire entity
46000
SEC CIK
0001799365

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Processa Pharmaceuticals, Inc.

Report date April 30, 2026 · Filed May 19, 2026 · Amendment

Section 16 reporting ended · disclosed 2026-05-19. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,481 Reported balance After 2026-04-30 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2026-04-30 · Purchase · Acquired 1,971 · Balance 7,481

F1: Shares adjusted to correct immaterial errors.

Common StockSEC Table I · non-derivativeIndirectBy CorLyst, LLC267 Reported balance Holding disclosure · report date 2026-04-30 · row 2 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 2 · Balance 267

Filing footnotes · ownership attribution and instrument terms

F1: Shares adjusted to correct immaterial errors.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 30, 2026 Filed May 1, 2026 20:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,986 $2.69 $5,342.34
Disclosure

SEC source: 0000897069-26-001000 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,496

Read SEC document
April 30, 2026 Filed May 19, 2026 21:17 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,971 $2.71 $5,341.41
Disclosure

SEC source: 0000897069-26-001154 · form4a.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,481

F1 · shares: Shares adjusted to correct immaterial errors.

F1 · price: Shares adjusted to correct immaterial errors.

F1 · balance_after: Shares adjusted to correct immaterial errors.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:50 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,799 $2.97 $5,343.03
Disclosure

SEC source: 0000897069-26-000904 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,510

Read SEC document
March 31, 2026 Filed Apr 1, 2026 21:08 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 2,107 $2.54 $5,341.25
Disclosure

SEC source: 0000897069-26-000743 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,711

Read SEC document
January 01, 2026 Filed Feb 4, 2026 22:04 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionRestricted Stock Units · Derivative 249 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-26-000218 · form4.xml · derivative · entry 3

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 249 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of vested restricted shares.

F1 · derivative.expiration_date: Distribution of vested restricted shares.

Read SEC document
January 01, 2026 Filed Feb 4, 2026 22:04 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 249 $0.00 $0.00
Disclosure

SEC source: 0000897069-26-000218 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 20:29 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantStock Options (Right to Buy) · Derivative 288,000 $0.00 Strike: $0.20 $0.00
Disclosure

SEC source: 0000897069-25-001549 · form4.xml · derivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,000

Underlying: Common Stock · 288,000 shares

Expires not disclosed

F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 20:29 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 96,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-25-001549 · form4.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

Read SEC document
July 24, 2025 Filed Jul 28, 2025 20:32 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 1,659,185 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-25-001219 · form4.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,672,087

Underlying: Common Stock · 1,659,185 shares

Expires not disclosed

F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,638,778 shares are subject to stockholder approval of the revised Omnibus Plan.

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.

Read SEC document
April 01, 2025 Filed Apr 11, 2025 21:17 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 3,311 $0.41 $1,364.13
Disclosure

SEC source: 0000897069-25-000789 · form4.xml · nonDerivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,626

Read SEC document
April 01, 2025 Filed Apr 11, 2025 21:17 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 15,059 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-25-000789 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
July 10, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 225 $1.71 $384.75
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 4

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,878

Read SEC document
July 10, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 644 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 3

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 404 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · derivative · entry 9

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,961

Underlying: Common Stock · 404 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 404 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · derivative · entry 8

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,557

Underlying: Common Stock · 404 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 2,425 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · derivative · entry 7

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,153

Underlying: Common Stock · 2,425 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 3,233 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · derivative · entry 6

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,728

Underlying: Common Stock · 3,233 shares

Expires not disclosed

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

Read SEC document
April 05, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 368 $2.79 $1,026.72
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,459

Read SEC document
April 05, 2024 Filed Aug 2, 2024 21:34 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,827

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:52 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionRestricted Stock Units · Derivative 1,675 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-000919 · form4.xml · derivative · entry 4

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,139

Underlying: Common Stock · 1,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of vested restricted shares.

F1 · derivative.expiration_date: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:52 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 368 $2.79 $1,026.72
Disclosure

SEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,458

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 20:52 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,826

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:38 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 48,490 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 3

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,475

Underlying: Common Stock · 48,490 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:38 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 75,907 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431,985

Underlying: Common Stock · 75,907 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
December 31, 2022 Filed Jan 4, 2023 22:38 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 13,851 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000320 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,073

Underlying: Common Stock · 13,851 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2022 Filed Oct 3, 2022 20:55 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 13,850 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-018061 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,227

Underlying: Common Stock · 13,850 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
August 05, 2022 Filed Aug 9, 2022 20:25 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-015305 · doc1.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,019

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Vesting of time-based restricted shares.

Read SEC document
June 30, 2022 Filed Jul 5, 2022 21:41 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 25,611 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-013685 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,377

Underlying: Common Stock · 25,611 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
April 01, 2022 Filed Apr 11, 2022 21:58 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 247,841 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008369 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,766

Underlying: Common Stock · 247,841 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:52 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 10,715 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-007998 · doc1.xml · derivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,781

Underlying: Common Stock · 10,715 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 22:32 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000304 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,722

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 6, 2022 22:28 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000779 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,780

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
November 01, 2021 Filed Apr 4, 2022 21:52 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 4,286 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-007998 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,066

Underlying: Common Stock · 4,286 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 20:49 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-017833 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,024

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Jan 6, 2022 20:58 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000710 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,058

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:40 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-21-014751 · doc1.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 395,418

F1 · price: Vesting of time-based restricted shares.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 1,907 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 3

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,034

Underlying: Common Stock · 10,034 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 12,858 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 2

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,858

Underlying: Common Stock · 12,858 shares

Expires not disclosed

F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals.

F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 20:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,572 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013191 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,572

Underlying: Common Stock · 8,572 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:13 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,127 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-011986 · doc1.xml · derivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.